Vyriad and Sanford Health begin Phase I viro-immunotherapy trial

US-based biopharmaceutical firm Vyriad has initiated a clinical trial at integrated health system Sanford Health to evaluate a genetically engineered virus for destroying therapy-resistant tumours.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news